1466 — Baijin Life Science Holdings Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsHighly SpeculativeSmall CapMomentum Trap

Annual cashflow statement for Baijin Life Science Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-280	-52.1	-15.5	8.73	-8.53
Depreciation
Amortisation
Non-Cash Items	208	39.1	11.1	-30.3	-14.8
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	70.7	-5.39	4.15	-1.4	15
Change in Accounts Receivable
Change in Inventories
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	2.33	-16.2	1.11	-21.5	-6.46
Capital Expenditures	-3.62	-0.025	-0.046	-0.026	-0.179
Purchase of Fixed Assets
Other Investing Cash Flow Items	42.8	0.163	-0.014	35.3	4.92
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	39.1	0.138	-0.06	35.3	4.74
Financing Cash Flow Items	-12	-5.65	-3.55	-0.067	-0.037
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-35.2	6.77	-1.72	3.7	0.819
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	6.05	-10.1	-0.839	17.7	-3.38